Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 1,201–1,300 of 1,448
The ABCA7 transporter, brain lipids and Alzheimer’s disease
Soscia, S. J., & Fitzgerald, M. L. (2013) · Clinical Lipidology · doi:10.2217/clp.12.91 · Cited by 4
Apolipoproteins in Different Amyloidoses
Sadowski, M., & Wısnıewskı, T. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_6 · Cited by 3
Banks, W. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_2 · Cited by 4
Gary, C., Hérard, A., Hanss, Z., & Dhénain, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00035 · Cited by 3
“, 2001) and/or to Aβ exportation outside the brain through the blood–brain barrier (BBB) (Shibata et al., 2000) and/or via the interstitial fluid (ISF) bulk flow into the cerebrospinal fluid (CSF), and from there into the bloodstream (Silverberg et al.”
BackgroundInfluentialPharmacokinetics of Systemic Drug Delivery
O’Connor, C., Ramanath, N., & Campbell, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813997-4.00003-7 · Cited by 4
Jiang, J., Okochi, M., Tagami, S., Nishitomi, K., Yanagida, K., NAKAYAMA, T., Tatsumi, S., Mori, K., & Takeda, M. (2008) · Psychogeriatrics · doi:10.1111/j.1479-8301.2008.00259.x · Cited by 3
Yamauchi, K., Tozuka, M., Hidaka, E., Ueno, I., Matsuda, K., & Katsuyama, T. (2003) · PubMed · Cited by 3
Nutrient signaling pathways regulate amyloid clearance and synaptic loss in Alzheimer’s diseasePreprint
Mondal, M., Bali, J., Tzioras, M., Paolicelli, R. C., Jawaid, A., Malnar, M., Dominko, K., Udayar, V., Halima, S. B., Vadodaria, K. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.13.381186 · Cited by 3
“…provides additional neuronal Aβ clearance through non-cell autonomous mechanisms via microglia (Chung et al., 1999), interstitial fluid to CSF bulk flow, efflux through blood brain barrier (Bell et al., 2009; Shibata et al., 2000) and enzymatic degradation (Iwata et al., 2000; Qiu et al., 1998).”
BackgroundRozeboom, A., Broekaart, D. W. M., Anink, J. J., Boonkamp, L., Idema, S., Teunissen, C. E., Aronica, E., Gorter, J. A., & van Vliet, E. A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115149 · Cited by 2
“LRP1 expression in brain capillaries decreases during aging in mice (Shibata et al., 2000) and rats (Osgood et al., 2017; Silverberg et al., 2010), in AD mouse model (Deane et al., 2004) as well as in AD patients (Deane et al., 2004; Donahue et al., 2006; Osgood et al., 2017; Shibata et al., 2000).”
Xie, Q., Chen, Z., Wang, J., Wang, Y., Zhang, H., Wang, X., Li, C., Wang, Y., Cong, L., Song, L., et al. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112372 · Cited by 2
Amyloid beta binding partners in the brain tissue of older adults
Oveisgharan, S., Yu, L., Wang, Y., Yang, J., Vialle, R. A., Lopes, K. D. P., Tasaki, S., Young‐Pearse, T. L., Jager, P. L. D., Petyuk, V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70882 · Cited by 2
Functions of the basal lamina and ApoE in cerebral amyloid angiopathy
Juan-Palencia, A., & Yao, Y. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00734-w · Cited by 2
Liu, Y., Yin, L., Zhang, P., & Li, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1825000 · Cited by 2
Animals Models of Normal Pressure Hydrocephalus
Klinge, P. M. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_31 · Cited by 2
Neuroprotective Effects of Extra‐Virgin Olive Oil and its Components in Alzheimer's Disease
Abuznait, A. H., Qosa, H., Mohamed, L. A., Batarseh, Y. S., & Kaddoumi, A. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch14 · Cited by 2
Yamada, S. (2017) · Spinal Surgery · doi:10.2531/spinalsurg.31.20 · Cited by 2
Self-citationKL-FGF23-VD Axis in Improving Late-Onset Alzheimer’s Disease by Modulating IKK/NF-κB Signal Pathway
Cai, Y., Hu, J., & He, M. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/3100621 · Cited by 2
“99% of patients belong to sporadic AD whose main pathological mechanism is that Aβ is abnormally cleavage and metabolized due to some factors including gene mutation, neurotransmitter disorder, oxidative stress, free radical damage, and inflammatory response, which result in the removal impairment of Aβ and thus lead…”
BackgroundRetractedCerebrospinal and Interstitial Fluids: Production, Outflow, and Circulation
Hladky, S. B., & Barrand, M. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_7 · Cited by 3
Diffusion Mediates Molecular Transport through the Perivascular Space in the Brain
Tanaka, M., Hirayoshi, Y., Minatani, S., Hasegawa, I., & Itoh, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052480 · Cited by 2
A circadian clock regulates the blood-brain barrier across phylogeny
Avila, A., & Zhang, S. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.04.004 · Cited by 2
Recent updates on immunotherapy in neurodegenerative diseases
Salunkhe, J., & Ugale, R. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149205 · Cited by 2
Biomarkers of Alzheimer’s disease
Pitt, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00048-8 · Cited by 3
Introduction to Alzheimer’s Disease
Manivasagam, T., Surya, R., Jayalakshmi, M., Thenmozhi, A. J., Prema, A., Qoronfleh, M. W., Alharbi, H. F., & Rajamani, Y. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-0677-2_1 · Cited by 3
Zetterberg, H. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.3.347 · Cited by 2
O’Leary, J. C., Koren, J., & Dickey, C. A. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9540-4 · Cited by 2
“The VSMC can clear Aβ by using lipoprotein receptor-related protein-1 to sequester it (Shibata et al. 2000; Urmoneit et al. 1997).”
BackgroundNeurochemical Effects of Long Term Consumption of Simple Carbohydrates
Farooqui, A. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-15254-7_3 · Cited by 2
Catabolism and Anabolism of Amyloid-β
Hashimoto, S., Nilsson, P., & Saido, T. C. (2015) · Springer eBooks · doi:10.1007/978-4-431-55763-0_19 · Cited by 2
Lipid metabolism in the central nervous system and neurodegenerative diseases
Hayashi, H. (2011) · Folia Pharmacologica Japonica · doi:10.1254/fpj.137.227 · Cited by 2
Regulation of the Extracellular Matrix by Heat Shock Proteins and Molecular Chaperones
Boel, N. M.-E., & Edkins, A. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-69042-1_6 · Cited by 3
Safety and Nanotoxicity Aspects of Nanomedicines for Brain-Targeted Drug Delivery
Catalán-Figueroa, J., & Morales, J. O. (2020) · Neuromethods · doi:10.1007/978-1-0716-0838-8_10 · Cited by 3
Dabbs, R. A., Wyatt, A. R., Yerbury, J. J., Ecroyd, H. W., & Wilson, M. R. (2010) · Topics in current chemistry · doi:10.1007/128_2010_85 · Cited by 2
Perspectives of Alzheimer's disease treatments
Davis, J. B., Bountra, C., & Richardson, J. C. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01226-2 · Cited by 3
Amyloid: Vascular and Parenchymal
Weller, R. O., Carare, R. O., & Boche, D. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00105-4 · Cited by 2
Angiotensin-converting enzyme cleavage of the Alzheimer's beta-amyloid peptide
Larmuth, K. (2015) · Open University of Cape Town (University of Cape Town) · Cited by 3
Genetic Studies of Alzheimer's Disease
Blom, E. S. (2008) · Uppsala University Publications (Uppsala University) · Cited by 2
Statistical modelling of blood flow and transport in brain micro-vascular networks
Goirand, F. (2021) · theses.fr (ABES) · doi:10.70675/fe984905zc014z4590z9ebez258704f735b1 · Cited by 3
Primary Cilia and Cardiovascular Risk Factors in Alzheimer's Disease
Sunderman, C. L., Forero, K. V., Alorjani, Q., Buqaileh, R., Gallagher, G. M., Ventresca, S. M., Messer, W. S., & AbouAlaiwi, W. A. (2025) · Brain Sciences · doi:10.3390/brainsci15091004 · Cited by 1
“In the BBB, the low-density lipoprotein receptor-related protein 1 (LRP1) plays a major role in maintaining A β homeostasis and mediates transport of A β across the BBB into circulation [105,106].”
Lower Plasma Amyloid Beta - 42 Levels Associated With Worse Survival in Patients With Glioma
Seo, K., Hwang, K., Noh, M., Park, J. J., Ahn, K., Ji, S. Y., Han, J. H., & Kim, C. (2023) · In Vivo · doi:10.21873/invivo.13455 · Cited by 1
“Amyloid precursor protein-derived Aβ42 is known to be transported across the blood-brain barrier in both directions and is mainly supplied from the brain (18, 19).”
BackgroundCerebrospinal Fluid Biomarkers of Alzheimer Disease
Васильевна, Н. К., Shpilyukova, Y. A., Шабалина, А. А., Fedotova, E. Y., & Illarioshkin, S. N. (2025) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1185 · Cited by 1
Bhargavan, B., Annadurai, N., & Kanmogne, G. D. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02197-4 · Cited by 1
“…glycation end products (RAGE), an influx receptor that binds and transports circulating plasma Aβ into the CNS [19, 20, 32, 70], and the low-density lipoprotein receptor–related protein-1 (LRP1), an efflux-clearance receptor that binds and trans-ports brain-derived Aβ into the blood [19, 108, 117].”
InfluentialArzola, E. P., Yu, G., Xiong, L., Lee, D., Wu, A., Paruchuri, S., Skinner, J., Wang, M., Zhang, B., Mei, L., et al. (2025) · Glia · doi:10.1002/glia.70114 · Cited by 1
Babu, P. R., Turner, C., & Ryznar, R. J. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01767-8 · Cited by 1
Garrahy, J. P. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251404970 · Cited by 2
“72,73 (cid:129) Glymphatic and perivascular clearance of A β can be impeded by inadequate sleep, cerebrovascular dysfunction, and reactive astrogliosis.”
Mechanistic modeling of amyloid dynamics relating to Alzheimer's disease progression
Przekwas, A. J., Norris, C., & Garimella, H. T. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1730480 · Cited by 1
“Impaired A β clearance across the BBB endothelial cells plays a crucial role in the pathogenesis of AD.”
InfluentialYin, W.-M., He, L.-C., Zhu, H., Cao, Y., Li, A.-M., Wang, Y.-C., & Xu, Y.-M. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116407 · Cited by 1
Han, Y., Luo, G., Huang, Y., Cai, Z., Su, W., Kuang, X., Huang, L., Wei, L., Ming, F., He, Z., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1794820 · Cited by 1
“Studies supporting this view demonstrate that soluble A β can be transported relatively freely across the BBB between the central nervous system and peripheral circulation (Shibata et al., 2000).”
Kumari, N., Kumari, S., Sharma, P., Dhapola, R., Paidlewar, M., & HariKrishnaReddy, D. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118107 · Cited by 1
Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations
Dayma, K., & Upadhyay, A. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.030 · Cited by 2
Baker, B., Emerson, S., Tran, T., Mohapatra, N., Wang, D., Zaw, T., Doshi, A. A., Lopez, J.-M., Hassan, D., Kumar, P., et al. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2698782 · Cited by 1
“In brain endothelium, LRP1 participates in handling of Aβ species and apolipoprotein-bound complexes, and LDL receptor family members provide a mechanistic link between corona composition (e.g., ApoE/clusterin enrichment) and routing behavior [20,21].”
Yao, M., Liu, A., Xing, L., Song, J., Yang, Y., Yue, X., & Li, H. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103260 · Cited by 1
Zheng, H., Li, Q., Luo, H., Yuan, Y., Zhang, N., Lu, Y., Duan, S., Zhong, J., Hb, Z., Liu, C. G., et al. (2026) · Advanced Science · doi:10.1002/advs.76761 · Cited by 2
Is amyloid beta peptide a driver of inflammaging?
Kechko, O. I., Moskalev, A. A., Franceschi, C., Mitkevich, V. A., & Makarov, A. А. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103280 · Cited by 1
The Molecular Basis of Alzheimer's Disease
Ingelsson, M., & Hyman, B. T. (2007) · Elsevier eBooks · doi:10.1016/b978-012369509-3.50018-4 · Cited by 1
Pathological Validation of Animal Models of Dementia
Pirici, D. N., Broeckhoven, C. V., & Kumar‐Singh, S. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_7 · Cited by 2
Recovery from ICH – Potential Targets
Yao, Y., & Tsirka, S. E. (2014) · InTech eBooks · doi:10.5772/58477 · Cited by 1
Lipoproteins and Apolipoproteins in Alzheimer's Disease
Matsubara, E. (2012) · InTech eBooks · doi:10.5772/45977 · Cited by 1
“In vivo relevance of LRP-1-mediated Aß transport has been confirmed in transgenic mice expressing low LRP-1-receptor and APP, which develops extensive Aß accumulation much faster than transgenic mice expressing high level of APP (20).”
BackgroundInfluentialMatsunaga, Y., & Suenaga, M. (2012) · Journal of Amino Acids · doi:10.1155/2012/206520 · Cited by 2
Zhu, M., Xu, W., Zhao, Z., Ma, G., Bao, M., & Sun, Z. (2012) · Biomedicine & Aging Pathology · doi:10.1016/j.biomag.2012.03.006 · Cited by 1
Abnormal Expression Level of BACE1 and RAGE of Hippocampus Related to Cognitive Impairment in SHR
Qiao, J., Wang, X., Lu, W., Wang, X., & Ma, A. (2014) · Cited by 1
Innate and adaptive glial cell responses in Alzheimer’s disease
Singh, A., & Singh, T. R. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00039 · Cited by 1
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs
Pang, K. S., Peng, H., Li, B. P., Wen, B., Noh, K., Xia, R., Toscan, A., Serson, S., Fraser, P. E., Tirona, R. G., et al. (2024) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2386 · Cited by 1
“…‐ onset) form of Alzheimer’s disease due to reduced A β peptide catabolism by neprilysin (Briones & Darw-ish, 2013; Hardy & Selkoe, 2002; Iwata et al., 2005; Yoon & Jo, 2012), and efflux by P ‐ gp and LRP1 (Briones & Darwish, 2013; Iwata et al., 2005; Shibata et al., 2000; Toornvliet et al., 2006).”
BackgroundThe role of human serum albumin in prevention and treatment of Alzheimer’s disease
Shevelyova, M. P., Deryusheva, E. I., Леонидовна, Н. Е., Валериевич, М. А., & Андреевна, Л. Е. (2023) · Журнал общей биологии · doi:10.31857/s0044459623020069 · Cited by 1
Cerebral Vascular Toxicity after Developmental Exposure to Arsenic (As) and Lead (Pb) Mixtures
Kiper, K., Mild, B., Chen, J., Yuan, C., Wells, E. M., Zheng, W., & Freeman, J. L. (2024) · Toxics · doi:10.3390/toxics12090624 · Cited by 1
The Guardian of the Brain: Understanding the Blood–Brain Barrier and its Role in CNS Drug Discovery
Rohfleisch, L., & Mishuris, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-61992-2_5 · Cited by 1
Banks, W. A. (2004) · Elsevier eBooks · doi:10.1016/b978-012639011-7/50012-7 · Cited by 1
Domain swapping as a molecular mechanism in amyloidosis
Wahlbom, M. (2007) · Lund University Publications (Lund University) · Cited by 1
Effects of a Peripheral Anti-Aβ Antibody on Plasma and CNS Aβ Clearance
Holtzman, D. M., Bales, K. R., Paul, S. M., & Demattos, R. B. (2003) · Springer eBooks · doi:10.1007/978-3-642-59332-1_8 · Cited by 1
Self-citationA potential molecule regulating the solubility and removal of amyloid-b
Zhou, X., & Wang, Y. (2011) · Cited by 1
Tachibana, T., & Kuwabara, T. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2019.01.006 · Cited by 1
Maliszewska‐Cyna, E. (2016) · TSpace (University of Toronto) · Cited by 1
Kim, J., Lipford, M. E., Barcus, R. A., Frye, B. M., Yuan, H., Lyu, Q., Hudson, J. P., Lockhart, S. N., Sutphen, C. L., Register, T. C., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6551242/v1 · Cited by 1
“Various mechanisms contribute to this clearance, including enzymatic degradation, cellular uptake, and transport across the blood-brain barrier (BBB) [7] and blood-cerebrospinal �uid barrier.”
Wei, B., Stitt, A. W., & Little, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.24.684393 · Cited by 1
Pinçon, A. (2014) · theses.fr (ABES) · doi:10.70675/6098b314z1123z4208za0e0z06d382f77a3e · Cited by 1
“has been implicated in the processing and clearance of Aβ peptides [16-18], and LDL-R deficit”
BackgroundInfluentialBorcuk, C. (2021) · theses.fr (ABES) · doi:10.70675/c316f2dcz54d3z41cfzb3f5z99c7b2d3cd95 · Cited by 1
Lam, S. (2021) · theses.fr (ABES) · doi:10.70675/60b353ffz56fcz41a2z9e53zf0d9ac078167 · Cited by 1
Mocquery-Corre, M., Cartier, L., Aziz, A.-I., Berquand, A., Clachet, J., Jean, C. M., Raymond, A., Btaouri, H. E., Dupuy, J., Hachet, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.17.732906 · Cited by 1
Leptin, Insulin and Blood-Brain Barrier Relations in Obesity
Banks, W. A., Nonaka, N., Shioda, S., Nakaoke, R., & Morley, J. E. (2005) · Elsevier eBooks · doi:10.1016/b978-84-8174-892-5.50012-7 · Cited by 1
Amyloid Beta and the Cerebral Vasculature
Grammas, P. (2005) · Humana Press eBooks · doi:10.1385/1-59259-824-2:267
Localisation of LRP1 in neurons and glia of the central nervous system
Herbert, R. P. (2014) · UTAS Research Repository · doi:10.25959/23242907
The novel role of the neuropeptides orexin and QRFP and their involvement in Alzheimer's disease
Davies, J. (2014) · Brunel University Research Archive (BURA) (Brunel University London)
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Coma, M. (2007) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Alternative signaling pathways triggered by different mechanisms of serpin endocytosis
Li, X. (2006) · edoc (University of Basel) · doi:10.5451/unibas-003907175
“It mediates the degradation of Aβ in complex with apoE or α2M [Kang et al., 2000;Shibata et al., 2000].”
BackgroundChapuis, J., & Lambert, J. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Transporters in the Blood-Brain Barrier
Ueno, M., Nakagawa, T., & Sakamoto, H. (2011) · InTech eBooks · doi:10.5772/21162
“LRP1 binds both ApoE/A complexes and A and regulates their clearance from brain to blood (Zlokovic, 2004; Shibata et al., 2000).”
BackgroundModulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
“The lipoprotein receptor low-density lipoprotein receptor-related protein 1 (LRP1) has been proposed to be one of the main mediators of this process (Deane et al., 2004; Shibata et al., 2000).”
Merlin, J. L. P. (2013) · Journal of the Chosun Natural Science · doi:10.13160/ricns.2013.6.3.125
“Aβ deposition may also increase brain vulnerability to ischemic injury[83,84], probably related to its additional vascular effects, including platelet aggregation[85], leukocyte activation, promotion of inammatory reaction[86,87], inhibition of endothelial proliferation[16,88], alteration of Cerebrovascular reactivity…”
BackgroundInfluentialApolipoproteins and β Amyloid Transport Pathway
Kamino, K., Kida, T., Tanaka, T., Tanii, H., Okochi, M., Kudo, T., Kobayashi, T., & Takeda, M. (2002) · Psychogeriatrics · doi:10.1111/j.1479-8301.2002.tb00078.x
Antibody Based Therapeutics for Alzheimer's Disease
Boddapati, S. P. (2011)
Haglund, M. (2005) · Lund University Publications (Lund University)
The older brain, inflammation, vaccination and the prevention of dementia
Neal, J. (2010) · Reviews in Clinical Gerontology · doi:10.1017/s0959259810000183
Amyloid-β Protofibrils in Alzheimer´s Disease : Focus on Antibodies, Inflammation and Astrocytes
Söllvander, S. (2015) · Uppsala University Publications (Uppsala University)
An Integrative View on Intra- and Inter-Cellular Cooperation Mechanisms in Alzheimer's Disease
Enciu, A., Parhon, C. I., & Babes, V. (2014)
Biologie, A. F., & Dieckmann, M. (2010)
ALTERNATIVE SIGNALING PATHWAYS TRIGGERED BY DIFFERENT MECHANISMS OF SERPIN ENDOCYTOSIS
Fakultät, P.-N. (2006)
Brain Effect Site Pharmacokinetics: Delivery of Biologics Across the Blood–Brain Barrier
Fricker, G., & Mahringer, A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse552
Role of TTR in A β peptide brain efflux - Impact in Alzheimer's disease
Gaiteiro, C. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/akv8-d088
Mitochondria-targeted amyloid: Relevance to neurotoxicity and Alzheimer's disease
Tillement, L. (2011) · DigitalGeorgetown (Georgetown University Library)
The Role of proteases and chaperones in extracellular proteostasis
Constantinescu, P. (2015) · Research Online (University of Wollongong)
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






